soul trial oral semaglutide cardiovascular outcomes 2024 2025 results 🧿 is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM Clinical Effectiveness and Safety of

or metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy

Additionally, glutathione plays a crucial role in liver detoxification, binding to toxins and heavy metals to facilitate their removal from the body

It acts as an antioxidant by neutralizing free radicals and reactive oxygen species (ROS), preventing them from causing harm to cellular structures such as DNA, proteins, and lipids

Larger, long-term clinical trials are still needed before strong conclusions can be drawn